How Big Is This Risk for Isis Pharmaceuticals, inc. Stock?

While the poor initial reception to Isis Pharmaceutical's Kynamro is upsetting, its performance might be the least of the company’s worries.

Jul 28, 2014 at 12:17PM

Isis Pharmaceuticals (NASDAQ:IONS) has a stable of candidates that companies several times its size would envy. With 32 candidates in development and five likely to be under regulatory review -- or approved -- within the next several years, it might have one of the most efficient discovery engines in the industry.

Now for the bad news, Isis has just one second-generation antisense drug on the market, and so far its launch has been disappointing. While the poor initial reception to Kynamro is upsetting, its performance might be the least of the company's worries. Let's see what is really keeping the RNA antisense pioneer awake at night.

Sinking flagship
Once touted as a potential Lipitor successor by CEO Stanley Crooke, Isis' flagship program, Kynamro, was almost bound to disappoint. While there's little doubt concerning its ability to decrease low density lipoprotein (LDL) cholesterol, serious adverse events prompted the FDA to limit its approval to patients with the extremely rare genetic condition, homozygous familial hypercholesterolemia, or HoFH. The FDA also insisted partners Isis and Sanofi run extensive long-term postmarketing studies to evaluate its long-term safety effects. Across the pond, the EMA refused to recommend its marketing authorization for any population ... twice.

Safety issues aside, Kynamro ran into competition at its outset. In the U.S., Juxtapid from Aegerion Pharmaceuticals won approval for HoFH just a month earlier than Kynamro where it has outperformed. Aegerion booked $48.5 million in Juxtapid sales last year and reached $27 million in the first quarter of 2014. Kynamro's first year sales were dismal enough that neither partner bothered to announce them, although the $3.1 million from licensing activities and royalties that Isis recorded last year suggest they were less than encouraging.

Further pressure for a limited Kynamro market could also be on the way from a new class of LDL cholesterol lowering therapies. Amgen's PCSK9 inhibitor evolocumab recently showed it could decrease LDL cholesterol in HoFH patients by 23% after 12 weeks. Kynamro partner Sanofi is also developing a PCSK9 inhibitor along with Regeneron. While the pair hasn't published HoFH data yet, evolocumab's success could be characteristic of the entire class.

Anti-drug antibodies
Potential cannibalization issues from marketing partner Sanofi might be worth fretting over, but Isis is facing a far more pressing issue. Long-term studies of Kynamro have unveiled serious tolerability issues that could be present across the company's entire pipeline.

Pooled phase 3 trial results showed 37.5% of patients developed antibodies specific to Kynamro. In other words, whenever these patients inject the drug, their immune systems recognize it and to differing degrees attack it. In those phase 3 trials the percentage of patients reporting flu-like symptoms was higher for patients with anti-Kynamro antibodies as for those without, about 25% and 39%, respectively.

Pooled phase 3 data is concerning, but the figures that should have Isis investors shivering come from a longer open-label extension study highlighted at an FDA advisory committee meeting. The data suggests the prevalence of anti-Kynamro antibodies rises as patients remain on therapy. A whopping 72% of patients in the extension study were positive for anti-Kynamro antibodies. Among anti-Kynamro antibody positive patients, over 71% exhibited flu-like symptoms.

Final thoughts
While Kynamro clearly has a host of issues, the main value driver for Isis is its bountiful clinical stage pipeline potentially worth nearly $9 billion per the 10-Q. A healthy stream of milestone revenue could be just waiting for the company's partners to invest moderate sums into clinical development of partnered programs.

Unfortunately that revenue potential won't be worth much if those partners can expect the same long-term tolerability issues present in Kynamro. Now, we don't know right now whether the problems are specific to Kynamro. But if they aren't -- if the antibody formation is a problem generalizable to all drugs in the pipeline -- then Isis could indeed have some additional difficulty.

Risk-free for 30 days: The Motley Fool's flagship service
Tom and David Gardner founded The Motley Fool over 20 years ago with the goal of helping the world invest...better. Their flagship service, Stock Advisor, has helped thousands of investors take control of their financial lives and beat the market. Click here to sign up today.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers